Tacrolimus øger blodkoncentrationen af phenytoin.

Tacrolimus has been shown to increase the blood level of phenytoin.

Tacrolimus øger blodkoncentrationen af fenytoin.

Tacrolimus has been shown to increase the blood level of phenytoin.

Metaboliske inducere Det er påvist klinisk, at de følgende midler nedsætter tacrolimus´ blodkoncentrationen:

Inducers of metabolism Clinically the following substances have been shown to decrease tacrolimus blood levels:

Hos de 5 børn der blev behandlet i 1 år, var blodkoncentrationerne vedvarende lave (højeste blodkoncentration var 1, 94 ng/ ml hos én patient).
http://www.emea.europa.eu/

In the 5 children treated for 1 year, blood concentrations were consistently low (maximum blood concentration was 1.94 ng/ml in 1 patient).
http://www.emea.europa.eu/

Vedligeholdelsesdoser af kortikosteroider reducerer tacrolimus blodkoncentration.

Maintenance doses of corticosteroids have been shown to reduce tacrolimus blood levels.

Omalizumabniveauer i mælken var 1, 5% af den maternale blodkoncentration.
http://www.emea.europa.eu/

Milk levels of omalizumab were 1.5% of the maternal blood concentration.
http://www.emea.europa.eu/

Metabolismehæmmere Følgende midler er vist at øge tacrolomus blodkoncentration:

Inhibitors of metabolism Clinically the following substances have been shown to increase tacrolimus blood levels:

Den højeste pimecrolimus-blodkoncentration målt hos én patient var 1, 4 ng/ml.

The highest pimecrolimus blood concentration was 1.4 ng/ml in one patient.

Pimecrolimus-blodkoncentrationerne var vedvarende lave, uanset graden af den behandlede læsion og varighed af behandlingen.

18 Pimecrolimus blood concentrations were consistently low regardless of the extent of lesions treated or duration of therapy.

Metaboliske inducere Følgende midler er vist klinisk at nedsætte tacrolimus blodkoncentration:
http://www.emea.europa.eu/

Inducers of metabolism Clinically the following substances have been shown to decrease tacrolimus blood levels:
http://www.emea.europa.eu/

6 Metabolismehæmmere Det er påvist, at de følgende midler øger tacrolimus´ blodkoncentration:
http://www.emea.europa.eu/

Inhibitors of metabolism Clinically the following substances have been shown to increase tacrolimus blood levels:
http://www.emea.europa.eu/

Vedligeholdelsesdoser af kortikosteroider reducerer tacrolimus´ blodkoncentration.
http://www.emea.europa.eu/

Maintenance doses of corticosteroids have been shown to reduce tacrolimus blood levels.
http://www.emea.europa.eu/

Dosering bør udsættes i tilfælde af forhøjede ciclosporin blodkoncentrationer.
http://www.emea.europa.eu/

Dosing should be delayed in the presence of elevated ciclosporin blood levels.
http://www.emea.europa.eu/

blodkoncentrationerne af lopinavir ved at hæmme enzymer, som metaboliserer det.

the blood levels of lopinavir by inhibiting enzymes which metabolise it.

I tilfælde af forhøjede ciclosporin- blodkoncentrationer bør doseringen udsættes.
http://www.emea.europa.eu/

Dosing should be delayed in the presence of elevated ciclosporin blood levels.
http://www.emea.europa.eu/

En hyppigere overvågning af den terapeutiske koncentration anbefales, indtil blodkoncentrationerne af disse produkter har stabiliseret sig.

More frequent therapeutic concentration monitoring is recommended until plasma levels of these products have been stabilised.

Blodkoncentrationerne af ciclosporin og patientens tilstand skal tages i betragtning, før man indleder behandling med Advagraf.

Advagraf therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient.

Det er imidlertid også nødvendigt at tage den kliniske tilstand i betragtning ved vurdering af blodkoncentrationerne.

It is necessary to consider the clinical condition of the patient when interpreting whole blood levels.

Exenatid udskilles primært i nyrerne, hvorfor hepatisk dysfunktion ikke forventes at påvirke blodkoncentrationer af exenatid.

Exenatide is cleared primarily by the kidney, therefore hepatic dysfunction is not expected to affect blood concentrations of exenatide.

Man ved ikke, om raltegravir har en betydelig indvirkning på andre HIV-lægemidlers blodkoncentrationer.

Raltegravir is not known to have an important effect on blood levels of other agents used to treat HIV.